Printer Friendly

IDEC PHARMACEUTICALS COMPLETES PATIENT ACCRUAL IN IDEC-C2B8 PHASE III PIVOTAL TRIAL

SAN DIEGO, March 7 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (Nasdaq: IDPH) today announced completion of patient accrual in its Phase III open label, single arm pivotal trial of IDEC-C2B8, immunotherapy for non-Hodgkin's B-cell lymphomas. Final results of the 150-patient trial are not anticipated until late 1996, to allow for patient follow-up and audit of clinical data.

IDEC-C2B8 is being jointly developed with Genentech, Inc. and Zenyaku Kogyo Co. Ltd. Additional IDEC-C2B8 clinical trials are ongoing in the U.S. and Canada, including protocols for the retreatment of patients who have responded to IDEC-C2B8 in clinical trials.

IDEC Pharmaceuticals focuses on developing targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC's products are primarily designed to act through immune mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. All of IDEC's products are designed for administration in outpatient settings, providing the opportunity to reduce overall treatment costs.

The statements made in this press release contain certain forward looking statements that involve a number of risks and uncertainties. Actual events or results may differ from the Company's expectations. In addition to the matters described in this press release, timelines for clinical activity, results of pending or future clinical trials, and changes in the status of the Company's collaborative relationships, as well as the risk factors listed from time to time in the Company's SEC reports, including but not limited to its report on Form 10-Q for the quarter ended September 30, 1995 as well as its Annual Reports on Form 10-K, may affect the actual results achieved by the Company.

IDEC Pharmaceuticals(R) is a registered U.S. trademark of the Company. The Company is located at 11011 Torreyana Road, San Diego, CA 92121.
 -0- 3/7/96


/CONTACT: Connie Matsui, Vice President, Planning & Resource Development, IDEC Pharmaceuticals Corp., 619-550-8656/

/IDEC Pharmaceuticals' press releases and quarterly reports are available at no charge through PR Newswire's "Company News On-Call" fax, 800-758-5804, extension 432581, or http://www.prnewswire.com/

(IDPH)

CO: IDEC Pharmaceuticals Corporation; Genentech Inc.; Zenyaku Kogyo Co. Ltd. ST: California IN: MTC SU: PDT

ST-MO -- LATH059 -- 1369 03/07/96 17:58 EST
COPYRIGHT 1996 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 7, 1996
Words:363
Previous Article:RISCORP AND COMPSOURCE FINALIZE AGREEMENT TO COMBINE THEIR NORTH CAROLINA WORKERS' COMP OPERATIONS
Next Article:HORIZON/CMS HEALTHCARE CORPORATION FILES LAWSUIT AGAINST TENET HEALTHCARE CORPORATION
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters